1. Improving Survival in Glioblastoma Multiforme

2. This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

3. Challenges in SOC in GBM

4. Case Study 1: Newly Diagnosed GBM

5. Case Study 1: Treatment

6. Addition of Bevacizumab to SOC in Newly Diagnosed Glioblastoma

7. Case Study 1: Treatment (cont)

8. Case Study 1: Treatment (cont)

9. Pseudoprogression and Treatment Effect

10. Pseudoprogression and Effect of Treatment (cont)

11. Maintenance With TTF Plus Temozolomide vs Temozolomide Alone

12. TTF Plus Temozolomide Results of Interim Analysis

13. TTF Plus Temozolomide Safety

14. Case Study 2: Relapsed Patient

15. SOC for Recurrent GBM

16. Bevacizumab and CCNU in Recurrent GBM

17. Bevacizumab in Recurrent GBM Safety

18. Carmustine Wafers

19. Emerging Novel Therapies for Patients With Relapsed Disease

20. Case Study 2: Relapsed Patient (cont)

21. Immunotherapies – Clinical Trials

22. Case Study 2: Relapsed Patient (cont)

23. TTF in Recurrent GBM

24. Prognostic Correlation of IDH1/2 Mutation in GBM

25. Conclusions

26. Abbreviations

27. Abbreviations (cont)